English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Although many patients with Hodgkin lymphoma (HL) achieve sustained remission following first-line chemotherapy with or without consolidation radiotherapy, there remain 5–10% who are refractory to first-line therapy and up to 30% of patients relapse.1, 2 Second-line treatment with multi-agent salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) provides durable clinical benefit in around 50% of patients or more.2, 3

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation